insulin secretagogues - DPP-4 inhibitors

Browse trials
Matrix  

Vildagliptindiabetes type 2, in all types of patients vs

all NS
Vildagliptin vs placebo (add on SU)

all NS
Vildagliptin vs acarbose

all NS
Vildagliptin vs voglibose

all NS
Vildagliptin vs MET

all NS
Vildagliptin vs metformin

all NS
Vildagliptin vs placebo

all NS
Vildagliptin vs placebo (add on current therapy)

all NS
Vildagliptin vs placebo (add on glimepiride)

all NS
Vildagliptin vs placebo (add on insulin)

Adverse events leading to treatment discontinuation by 850% adverse event
Vildagliptin vs placebo (add on MET)

all NS
Vildagliptin vs placebo (on top pioglitazone)

all NS
Vildagliptin vs gliclazide

all NS
Vildagliptin vs gliclazide (add on MET)

all NS
Vildagliptin vs glimepiride (add on MET)

all NS
Vildagliptin vs Sulfonylurea (add on to MET)

all NS
Vildagliptin vs TZD (add on MET)

all NS
Vildagliptin vs pioglitazone

all NS
Vildagliptin vs pioglitazone (add on MET)

all NS
Vildagliptin vs placebo (add on TZD)

all NS
Vildagliptin vs rosiglitazone

all NS
Alogliptindiabetes type 2, in all types of patients vs

all NS
Alogliptin vs placebo

all NS
Alogliptin vs placebo (add on MET)

all NS
Linagliptindiabetes type 2, in all types of patients vs

all NS
Linagliptin vs Metformin + sulfonylurea

all NS
Linagliptin vs placebo

all NS
Linagliptin vs placebo (add on MET)

all NS
Linagliptin vs placebo (add on pioglitazone)

all NS
Linagliptin vs placebo (add on SU)

all NS
Linagliptin vs glimepiride

cardiovascular events by 54% suggested
Linagliptin vs glimepiride (add on MET)

all NS
Saxagliptindiabetes type 2, in all types of patients vs

all NS
Saxagliptin vs glyburide uptitration

all NS
Saxagliptin vs metformin up to 2000mg

all NS
Saxagliptin vs placebo

all NS
Saxagliptin vs placebo (add on current treatment)

all NS
Saxagliptin vs placebo (add on insulin)

all NS
Saxagliptin vs placebo (add on MET)

all NS
Saxagliptin vs placebo (add on TZD)

all NS
Saxagliptin vs placebo (monotherapy)

all NS
Saxagliptin vs sitagliptin (add on MET)

all NS
Saxagliptin vs glipizide

all NS
Sitagliptindiabetes type 2, in all types of patients vs

all NS
Sitagliptin vs control (add on MET)

all NS
Sitagliptin vs rosiglitazone (add on MET)

all NS
Sitagliptin vs voglibose

all NS
Sitagliptin vs metformin+pio

all NS
Sitagliptin vs placebo

all NS
Sitagliptin vs placebo (add on insulin+/-MET)

all NS
Sitagliptin vs placebo (add on MET)

all NS
Sitagliptin vs placebo (add on PIO)

all NS
Sitagliptin vs placebo (on top PIO)

Adverse events leading to treatment discontinuation by 459% adverse event
Sitagliptin vs placebo (on-top glimepiride+/- metformine)

all NS
Sitagliptin vs glimepiride (add on MET)

all NS
Sitagliptin vs Sulphonylurea (on top MET)

all NS
Sitagliptin vs metformin

all NS
Sitagliptin vs glipizide

all NS
Sitagliptin vs pioglitazone

all NS

 


- About - Browse pathology | treatment - Site map - Credits Made with in Lyon - Contact us - Privacy policy - Licence Creative Commons